PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19000912-3	2009	Mice genetically deficient in IDO-1 were not protected against CM, but partial protection was observed in C57BL/6 mice treated with Ro 61-8048, an inhibitor of kynurenine-3-hydroxylase.	Ro 61-8048	132-142	kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)	Mus musculus	160-184	
19339256-8	2009	In the current study, Ro-61-8048, a high affinity kynurenine-3-monooxygenase inhibitor, was used to determine the effect of manipulating the kynurenine pathway in a highly reproducible mouse model of human African trypanosomiasis.	Ro 61-8048	22-32	kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)	Mus musculus	50-76	
35189673-2	2022	We previously demonstrated that inhibition of kynurenine 3-monooxygenase (KMO) using Ro 61-8048 reduces ethanol consumption in a binge drinking model.	Ro 61-8048	85-95	kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)	Mus musculus	46-72	
34183381-3	2021	In this study, the role of kynurenine 3-monooxygenase (KMO) in immune regulation was examined in LPS-induced endotoxemia using KMO-/- and KMO+/+ mice treated with the KMO inhibitor Ro61-8048.	Ro 61-8048	181-190	kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)	Mus musculus	167-170	
35189673-2	2022	We previously demonstrated that inhibition of kynurenine 3-monooxygenase (KMO) using Ro 61-8048 reduces ethanol consumption in a binge drinking model.	Ro 61-8048	85-95	kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)	Mus musculus	74-77	
28709913-9	2017	In addition, intracerebroventricular administration of the KMO inhibitor Ro 61-8048 abrogated depression-like behavior without affecting mechanical allodynia after SNI.	Ro 61-8048	73-83	kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)	Mus musculus	59-62	
32505212-13	2020	KP modulation by KMO inhibition with Ro 61-8048 led to significantly greater numbers of Foxp3 cells (p < 0.05) in Ro 61-8048 treated mice and even more significant amelioration of EAE disease compared to the 1-MT treatment groups.	Ro 61-8048	37-47	kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)	Mus musculus	17-20	
32505212-13	2020	KP modulation by KMO inhibition with Ro 61-8048 led to significantly greater numbers of Foxp3 cells (p < 0.05) in Ro 61-8048 treated mice and even more significant amelioration of EAE disease compared to the 1-MT treatment groups.	Ro 61-8048	114-124	kynurenine 3-monooxygenase (kynurenine 3-hydroxylase)	Mus musculus	17-20